Second-Line Regorafenib Extends Survival in Sorafenib-Tolerant HCC Patients
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
In this video, Richard S. Finn, MD, of the David Geffen School of Medicine at UCLA, discusses an exploratory analysis of the RESORCE trial. The trial tested regorafenib vs placebo after radiographic progression on sorafenib in patients with hepatocellular carcinoma (HCC).
Dr. Finn presented data from the exploratory analysis (abstract 344) at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco. The data showed that sorafenib-tolerant HCC patients who went on to receive regorafenib had a median overall survival of 26 months compared with 19.2 months in those who received placebo.
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
